Showing 42,761 - 42,780 results of 44,218 for search '(( 50 ((ppm decrease) OR (a decrease)) ) OR ( 5 ((mean decrease) OR (nn decrease)) ))', query time: 1.06s Refine Results
  1. 42761

    Downregulation of ATM1 affects iron-sulfur cluster proteins in <i>Toxoplasma</i> and iron levels in <i>Plasmodium</i>. by Deepti Shrivastava (17715780)

    Published 2024
    “…Unchanged proteins are displayed in black, while significantly altered proteins are displayed in grey (< 1.5-fold change (FC), local false discovery rate, LFDR < 0.05) or in blue (>1.5-fold increased; LFDR < 0.05) or red (> 1.5-fold decreased; LFDR < 0.05). …”
  2. 42762

    DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Con... by Melanie Thompson (207727)

    Published 2016
    “…<div><p>GV-TH-01, a Phase 1 open-label trial of a DNA prime—Modified Vaccinia Ankara (MVA) boost vaccine (GOVX-B11), was undertaken in HIV infected participants on antiretroviral treatment (ART) to evaluate safety and vaccine-elicited T cell responses, and explore the ability of elicited CD8+ T cells to control viral rebound during analytical treatment interruption (TI). …”
  3. 42763

    datasheet1_The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures.pdf by Evelien Moorkens (4723848)

    Published 2021
    “…When reported, discounts/rebates on originator adalimumab after loss of exclusivity ranged from 0% to approximately 26% (Romania), 60% (Poland), 80% (Denmark, Italy, Norway), and 80–90% (Netherlands), leading to actual prices per pen or syringe between €412 (Finland) and €50 – €99 (Netherlands). To leverage competition following entry of biosimilar adalimumab, only a few countries adopted measures specifically for adalimumab in addition to general policies regarding biosimilars. …”
  4. 42764

    Computational Analysis of Target Site Occurrence by Julius Brennecke (2231)

    Published 2013
    “…<div><p>(A) Genome-wide occurrence of conserved 5′ seed matches. …”
  5. 42765

    Toll-Like Receptor-2 Mediates Diet and/or Pathogen Associated Atherosclerosis: Proteomic Findings by Monika Madan (95727)

    Published 2008
    “…</p><h3>Methods and Results</h3><p>To explore the role of TLR2 in inflammation- and infection-associated atherosclerosis, 10 week-old ApoE<sup>+/−</sup>-TLR2<sup>+/+</sup>, ApoE<sup>+/−</sup>-TLR2<sup>+/−</sup> and ApoE<sup>+/−</sup>-TLR2<sup>−/−</sup> mice were fed either a high fat diet or a regular chow diet. All mice were inoculated intravenously, once per week for 24 consecutive weeks, with 50 µl live <em>Porphyromonas gingivalis</em> (<em>P.g</em>) (10<sup>7</sup> CFU) or vehicle (normal saline). …”
  6. 42766

    Thymoquinone loaded nanoemulgel in streptozotocin induced diabetic wound by Urati Anuradha (20306190)

    Published 2024
    “…<p><b>Aim:</b> To treat diabetic wound healing with a novel Thymoquinone (TQ) loaded nanoformulation by using combination of essentials oils.…”
  7. 42767

    Image_8_Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphom... by Fen Yang (287005)

    Published 2018
    “…</p><p>Results: In this phase Ia study, a total of eight subjects participated. VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (C<sub>max</sub>, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC<sub>0-Inf</sub>, 222.1 ng/mL h), markedly decreased distribution volume (V<sub>z</sub>, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower C<sub>max</sub> (26.6 ng/mL) and AUC<sub>0-Inf</sub> (95.1 ng/mL h), larger V<sub>z</sub> (688.8 L) and CL (22.1 L/h) for VSI. …”
  8. 42768

    Image_2_Combined Effect of CYP2C19 Genetic Polymorphisms and C-Reactive Protein on Voriconazole Exposure and Dosing in Immunocompromised Children.JPEG by Juan Chen (61123)

    Published 2022
    “…Covariates associated with voriconazole plasma concentrations and dose requirements were adjusted by using generalized linear mixed-effect models.</p>Results<p>A total of 682 voriconazole steady-state trough concentrations from 91 Chinese pediatric patients were included. …”
  9. 42769

    Image_5_Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphom... by Fen Yang (287005)

    Published 2018
    “…</p><p>Results: In this phase Ia study, a total of eight subjects participated. VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (C<sub>max</sub>, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC<sub>0-Inf</sub>, 222.1 ng/mL h), markedly decreased distribution volume (V<sub>z</sub>, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower C<sub>max</sub> (26.6 ng/mL) and AUC<sub>0-Inf</sub> (95.1 ng/mL h), larger V<sub>z</sub> (688.8 L) and CL (22.1 L/h) for VSI. …”
  10. 42770

    4-Octyl itaconate attenuates renal tubular injury in db/db mice by activating Nrf2 and promoting PGC-1α-mediated mitochondrial biogenesis by Muqing Shao (15238576)

    Published 2024
    “…<i>Irg1</i> knockout mice were generated. db/db mice were treated with 4-octyl itaconate (4-OI, 50 mg/kg), a derivative of itaconate, for 4 weeks. …”
  11. 42771

    Image_1_Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphom... by Fen Yang (287005)

    Published 2018
    “…</p><p>Results: In this phase Ia study, a total of eight subjects participated. VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (C<sub>max</sub>, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC<sub>0-Inf</sub>, 222.1 ng/mL h), markedly decreased distribution volume (V<sub>z</sub>, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower C<sub>max</sub> (26.6 ng/mL) and AUC<sub>0-Inf</sub> (95.1 ng/mL h), larger V<sub>z</sub> (688.8 L) and CL (22.1 L/h) for VSI. …”
  12. 42772

    Data_Sheet_1_Macrophage Depletion in Elderly Mice Improves Response to Tumor Immunotherapy, Increases Anti-tumor T Cell Activity and Reduces Treatment-Induced Cachexia.PDF by Lelinh Duong (5932946)

    Published 2018
    “…The immune system plays a critical role in the effectiveness of many anti-cancer therapies in young hosts via tumor-specific T cells. …”
  13. 42773

    Image_6_Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphom... by Fen Yang (287005)

    Published 2018
    “…</p><p>Results: In this phase Ia study, a total of eight subjects participated. VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (C<sub>max</sub>, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC<sub>0-Inf</sub>, 222.1 ng/mL h), markedly decreased distribution volume (V<sub>z</sub>, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower C<sub>max</sub> (26.6 ng/mL) and AUC<sub>0-Inf</sub> (95.1 ng/mL h), larger V<sub>z</sub> (688.8 L) and CL (22.1 L/h) for VSI. …”
  14. 42774

    Identification of whole blood mRNA and microRNA biomarkers of tissue damage and immune function resulting from amphetamine exposure or heat stroke in adult male rats by Luísa Camacho (5508251)

    Published 2019
    “…Most transcripts specific for T-cells decreased 50–70% after AMPH exposure or EIH, with the noted exception of <i>Ccr5</i> and <i>Chst12</i>. …”
  15. 42775

    Image_7_Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphom... by Fen Yang (287005)

    Published 2018
    “…</p><p>Results: In this phase Ia study, a total of eight subjects participated. VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (C<sub>max</sub>, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC<sub>0-Inf</sub>, 222.1 ng/mL h), markedly decreased distribution volume (V<sub>z</sub>, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower C<sub>max</sub> (26.6 ng/mL) and AUC<sub>0-Inf</sub> (95.1 ng/mL h), larger V<sub>z</sub> (688.8 L) and CL (22.1 L/h) for VSI. …”
  16. 42776

    Image_3_Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphom... by Fen Yang (287005)

    Published 2018
    “…</p><p>Results: In this phase Ia study, a total of eight subjects participated. VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (C<sub>max</sub>, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC<sub>0-Inf</sub>, 222.1 ng/mL h), markedly decreased distribution volume (V<sub>z</sub>, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower C<sub>max</sub> (26.6 ng/mL) and AUC<sub>0-Inf</sub> (95.1 ng/mL h), larger V<sub>z</sub> (688.8 L) and CL (22.1 L/h) for VSI. …”
  17. 42777

    Image_2_Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphom... by Fen Yang (287005)

    Published 2018
    “…</p><p>Results: In this phase Ia study, a total of eight subjects participated. VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (C<sub>max</sub>, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC<sub>0-Inf</sub>, 222.1 ng/mL h), markedly decreased distribution volume (V<sub>z</sub>, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower C<sub>max</sub> (26.6 ng/mL) and AUC<sub>0-Inf</sub> (95.1 ng/mL h), larger V<sub>z</sub> (688.8 L) and CL (22.1 L/h) for VSI. …”
  18. 42778

    Image_4_Pharmacokinetic Behavior of Vincristine and Safety Following Intravenous Administration of Vincristine Sulfate Liposome Injection in Chinese Patients With Malignant Lymphom... by Fen Yang (287005)

    Published 2018
    “…</p><p>Results: In this phase Ia study, a total of eight subjects participated. VCR elimination from the circulation after injection of VSLI was characterized by a significantly increased maximum concentration (C<sub>max</sub>, 86.6 ng/mL) and plasma area under the plasma concentration-time curve from zero to infinity (AUC<sub>0-Inf</sub>, 222.1 ng/mL h), markedly decreased distribution volume (V<sub>z</sub>, 224.1 L) and plasma clearance (CL, 8.9 L/h) compared to lower C<sub>max</sub> (26.6 ng/mL) and AUC<sub>0-Inf</sub> (95.1 ng/mL h), larger V<sub>z</sub> (688.8 L) and CL (22.1 L/h) for VSI. …”
  19. 42779

    Image_1_Combined Effect of CYP2C19 Genetic Polymorphisms and C-Reactive Protein on Voriconazole Exposure and Dosing in Immunocompromised Children.JPEG by Juan Chen (61123)

    Published 2022
    “…Covariates associated with voriconazole plasma concentrations and dose requirements were adjusted by using generalized linear mixed-effect models.</p>Results<p>A total of 682 voriconazole steady-state trough concentrations from 91 Chinese pediatric patients were included. …”
  20. 42780